TABLE 3.
Available data, n (%) | Overall (n = 326) | |
---|---|---|
Patient characteristics | ||
Sex, n (%) | ||
Female | 326 (100) | 204 (62.6) |
Male | 122 (37.4) | |
LSM (kPa), median (IQR) | 116 (35.6) | 5.9 (4.4–10.4) |
LSM ≥ 10 kPa, n (%) | 30 (9.2) | |
LSM ≥ 15 kPa, n (%) | 17 (5.2) | |
LSM ≥ 25 kPa, n (%) | 8 (2.5) | |
CAP (dB/m), median (IQR) | 226 (192–271) | |
CAP ≥248 dB/m, n (%) | 37 (11.3) | |
CAP >275 dB/m, n (%) | 23 (7.1) | |
APRI score, median (IQR) | 0.26 (0.18–0.37) | |
<0.5, n (%) | 209 (64.1) | 176 (54.0) |
<1.0, n (%) | 193 (59.2) | |
>1.5, n (%) | 8 (2.5) | |
>2.0, n (%) | 5 (1.5) | |
FIB‐4 score, median (IQR) | 1.34 (0.84–1.96) | |
<1.3, n (%) | 207 (63.5) | 100 (30.7) |
1.3–2.67, n (%) | 80 (24.5) | |
>2.67, n (%) | 27 (8.3) | |
Haemoglobin (g/dL), mean (SD) | 212 (65.0) | 13.9 (1.6) |
Platelet count (G/L), median (IQR) | 212 (65.0) | 209 (168–255) |
WBC (G/L), median (IQR) | 212 (65.0) | 6.7 (5.4–8.4) |
INR, mean (SD) | 193 (59.2) | 1.1 (0.2) |
Bilirubin (mg/dL), median (IQR) | 212 (65.0) | 0.4 (0.3–0.7) |
Albumin (mg/dL), mean (SD) | 209 (64.1) | 44.0 (4.2) |
AST (IU/L), median (IQR) | 205 (62.9) | 23 (18–29) |
ALT (IU/L), median (IQR) | 205 (62.9) | 20 (14–27) |
>ULN, n (%) | 13 (4.0) | |
AP (IU/L), median (IQR) | 212 (65.0) | 75 (62–93) |
gGT (IU/L), median (IQR) | 212 (65.0) | 21 (15–35) |
> ULN, n (%) | 28 (8.6) | |
CRP (mg/dL), median (IQR) | 149 (58) | 0.1 (0.1–0.4) |
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; APRI, AST to PLT ratio‐index; AST, aspartate aminotransferase; CAP, continuous attenuation parameter; CRP, C‐reactive protein; gGT, gammaglutamyl transferase; HCV, hepatitis C virus; INR, international normalised ratio; IQR, interquartile range; LSM, liver stiffness measurement; n, number; SD, standard deviation; SVR, sustained virological response; ULN, upper limit of normal; WBC, white‐cell blood count.